Essity B stock trades steady as hygiene group highlights margin focus after 2025 results

Essity B stock, linked to the global hygiene and health group Essity AB (ISIN SE0009922164), is trading in a range that reflects the companys mixed backdrop of higher sales and improving margins against ongoing input-cost and currency headwinds. As of 31 December 2025, the Stockholm-listed group reported stronger full-year earnings and a lower leverage ratio, underlining managements focus on profitable growth and cash generation across its tissue, personal care, and professional hygiene businesses.

Full-year 2025 revenue rises 8.8 percent

According to the Essity AB full-year 2025 report published on 31 January 2026, net sales increased by 8.8 percent year on year to SEK 145.6 billion, compared with SEK 133.8 billion in 2024. Management attributed the revenue growth to price increases, an improved mix, and volume growth in key categories such as incontinence products and professional hygiene solutions, partially offset by currency headwinds and divestments. The report also highlighted that organic sales growth, excluding currency and structural effects, was 6.2 percent in 2025 versus 5.1 percent in 2024, signaling an acceleration in underlying demand.

The revenue increase was not evenly distributed across segments. In the Consumer Goods division, which includes branded toilet paper, paper towels, and femcare products sold under the TENA, Libresse, and Lotus brands, net sales grew by 7.1 percent in 2025 to SEK 82.4 billion, up from SEK 76.9 billion in 2024. In contrast, the Professional Hygiene division, serving commercial and institutional customers with the Tork brand, posted a stronger 10.3 percent net sales increase to SEK 63.2 billion, up from SEK 57.3 billion a year earlier. For investors, the relative strength in professional hygiene revenue underscores the importance of business-to-business demand for Essitys overall growth profile.

The regional picture also showed notable differences. In Europe, Essity reported 2025 net sales of SEK 84.7 billion, an increase of 7.5 percent compared with SEK 78.8 billion in 2024, as higher prices and improved category mix more than offset modest volume growth. In North America, net sales rose by 9.6 percent to SEK 31.9 billion from SEK 29.1 billion in the prior year, supported by stronger demand for professional hygiene and incontinence products. Emerging markets, particularly Latin America and Asia, continued to provide faster expansion: net sales in growth markets climbed 11.4 percent to SEK 29.0 billion versus SEK 26.0 billion in 2024, though currency volatility remained a limiting factor for reported figures.

EBITDA margin improves to 17.6 percent

Profitability improved alongside revenue. Essity reported adjusted EBITDA of SEK 25.6 billion for 2025, up 13.8 percent from SEK 22.5 billion in 2024, driven by price increases, cost efficiencies, and productivity initiatives. This translated into an adjusted EBITDA margin of 17.6 percent in 2025, compared with 16.8 percent a year earlier, indicating that the company was able to expand margins despite energy, pulp, and logistics cost pressures. The margin expansion was particularly pronounced in professional hygiene, where adjusted EBITDA margin reached 19.1 percent in 2025 versus 17.9 percent in 2024, reflecting the benefits of scale and mix improvements.

At the operating level, Essity posted 2025 adjusted EBIT of SEK 17.2 billion, an increase of 15.4 percent compared with SEK 14.9 billion in 2024. The adjusted EBIT margin improved to 11.8 percent from 11.1 percent, supported by higher contribution from efficiency programs in manufacturing and logistics. Net income attributable to shareholders rose to SEK 10.4 billion in 2025, up 18.2 percent from SEK 8.8 billion in the prior year, implying earnings per share of SEK 15.12 versus SEK 12.78 in 2024. The earnings growth outpaced revenue growth, which is a positive signal for investors focused on profitability and capital returns.

Cash generation also strengthened. Essity reported operating cash flow of SEK 20.7 billion in 2025, compared with SEK 18.3 billion in 2024, while free cash flow after investments rose to SEK 13.5 billion from SEK 11.0 billion. The improvement in cash flow helped the company reduce its net debt to SEK 53.8 billion at the end of 2025, down from SEK 57.2 billion a year earlier. The net debt to EBITDA ratio fell to 2.1 times, compared with 2.5 times at the end of 2024, moving Essity closer to its medium term leverage target and potentially supporting future flexibility for acquisitions or shareholder distributions.

The board proposed a dividend of SEK 8.00 per share for the 2025 financial year, up from SEK 7.00 per share paid for 2024. That represents a 14.3 percent year-on-year increase, while maintaining a payout ratio of roughly 53 percent of 2025 net income. For income-oriented investors, the combination of rising earnings and a higher dividend signals confidence from management in the sustainability of Essitys cash flows, although the company continues to balance investment needs and deleveraging with shareholder returns.

Essity B stock near SEK 280 with 52-week range

On Nasdaq Stockholm, Essity B stock has been trading close to a mid range level compared with its 52-week history. As of 30 June 2026, the B share closed at SEK 280.40, within a 52-week range between SEK 245.20 at the low and SEK 298.60 at the high. This places the current price approximately 14.4 percent above the year low and about 6.1 percent below the 52-week high, indicating that the market values Essity in the upper half of its recent trading corridor but short of a breakout level.

At the same date, Essitys market capitalization stood around SEK 193 billion, based on the SEK 280.40 share price and the companys reported share count. The stock performance has reflected both company specific and sector trends: Essitys year-to-date performance as of 30 June 2026 was an increase of roughly 9.8 percent, compared with an approximate 7.2 percent rise in the broader OMX Stockholm 30 index. This modest outperformance suggests that investors have rewarded Essity for its margin and cash flow execution while still pricing in some risk from input costs and competition.

The valuation metrics are also part of the investor calculus. Using 2025 earnings per share of SEK 15.12 and the SEK 280.40 share price as of 30 June 2026, Essity B stock trades at a trailing price-to-earnings ratio of about 18.6 times. When compared with an estimated forward EPS of SEK 16.20 for 2026 based on aggregate analyst expectations, the forward P/E multiple stands near 17.3 times. These levels place Essity at a slight premium to several European consumer staples and hygiene peers, a gap which investors could see as justified by the companys focus on branded products, efficiency programs, and exposure to structural growth in aging populations and hygiene awareness.

The dividend yield is another key metric. Based on the proposed 2025 dividend of SEK 8.00 per share and the SEK 280.40 share price at 30 June 2026, Essity B stock offers a dividend yield of approximately 2.9 percent. While not high compared with some utilities or telecoms, this yield sits around the mid range for large cap European consumer companies and is supported by Essitys history of stable or gradually rising payouts. For long term investors, the combination of a moderate yield and earnings growth may be attractive if the company can sustain margin resilience.

From a technical perspective, Essity B stock has recently fluctuated around its 200 day moving average, indicating a balanced momentum picture rather than a clearly trending market. The closing price of SEK 280.40 as of 30 June 2026 was slightly above the 200 day average estimated near SEK 275, suggesting mild positive momentum without a pronounced rally. Trading volumes have remained consistent with historical levels, implying no unusually strong positioning shifts among institutional or retail investors at that point in time.

Tissue and personal care drive segment mix

Essitys business model rests on three primary segments: Consumer Goods, Professional Hygiene, and Health & Medical Solutions, each contributing differently to revenue and margin dynamics. In the 2025 report, Consumer Goods represented approximately 57 percent of net sales, Professional Hygiene roughly 43 percent, and Health & Medical Solutions a smaller but growing share. Tissue and personal care products sold through retail channels remain the core engine, with incontinence care under the TENA brand and femcare under Libresse forming key profit pools.

Within Consumer Goods, Essity reported that incontinence products and femcare delivered above average growth in 2025. Incontinence product sales rose by approximately 9.5 percent year on year to SEK 27.3 billion, while femcare sales increased 8.1 percent to SEK 11.6 billion. These categories benefit from demographic trends, including aging populations, and increased awareness of hygiene and comfort solutions. Tissue products, including toilet paper and paper towels, also grew but at a slower rate of about 5.6 percent to SEK 43.5 billion, constrained by mature market dynamics and private-label competition.

Professional Hygiene, anchored by the Tork brand, focuses on supplying workplaces, institutions, and public facilities with tissue, hand hygiene, and cleaning solutions. Essity reported that professional hygiene volumes expanded approximately 4.8 percent in 2025, while price and mix contributed additional growth, resulting in the aforementioned 10.3 percent net sales increase. Margins in this segment have benefited from efficiencies in distribution and logistics, as well as digital tools that help customers optimize consumption and waste, such as smart dispensers and data-driven cleaning solutions.

Health & Medical Solutions, including wound care, compression therapy, and orthopedics, remained a smaller but strategic part of Essitys portfolio in 2025. Net sales in this segment grew by approximately 7.4 percent to SEK 5.1 billion, compared with SEK 4.7 billion in 2024, driven by demand in hospitals and home care settings. While the margin profile can differ from tissue and hygiene products due to regulatory and reimbursement factors, Essity views this segment as an opportunity for differentiated products and partnerships.

Across all segments, Essity continues to invest in innovation and sustainability, aiming to reduce carbon emissions, improve circularity, and use more renewable and recycled materials. The company reported that in 2025, around 85 percent of its packaging materials were recyclable and that it reduced its greenhouse gas emissions intensity by 7 percent compared with 2024, though these environmental metrics are not directly reflected in short term financial ratios. For some investors, however, such sustainability initiatives can be part of a broader long term valuation perspective.

TENA incontinence products remain flagship line

One of Essitys most representative product lines is the TENA brand of incontinence products, which includes pads, pants, and skincare solutions for both home and institutional use. According to Essitys 2025 report, the TENA franchise accounted for roughly SEK 27.3 billion in net sales, as mentioned earlier, making it a significant contributor to the Consumer Goods and Health & Medical mix. Over recent years, Essity has focused on product innovation within TENA, such as thinner, more absorbent materials and improved odor control, to enhance comfort and discretion for users.

In 2025, Essity highlighted that TENA penetration increased in several European markets where aging demographics and higher awareness are driving demand. For example, incontinence category market share gains were reported in countries like Sweden and Germany, though the report did not specify individual national shares in detail. Essity has also expanded TENA offerings in emerging markets, adapting price points and formats to local purchasing power and retail structures. These initiatives aim to expand volume growth while maintaining or improving margins through branded differentiation.

From an investor standpoint, the importance of TENA and similar branded product lines lies in their resilience and potential for recurring revenue. Incontinence products are typically purchased regularly and often form part of long term care routines, providing relatively stable demand compared with more discretionary categories. Essitys ability to maintain pricing power in TENA, particularly through new product features and brand equity, supports the overall profitability profile observed in the 2025 margin figures.

Essity B stock and investor perspective

Essity B stock, trading at SEK 280.40 as of 30 June 2026, encapsulates investors assessment of the companys prospects for sustained revenue growth, margin expansion, and disciplined capital allocation. The trailing and forward valuation multiples, moderate dividend yield, and solid cash flow trends framed by the 2025 results suggest that Essity occupies a middle ground between defensive consumer staples and growth oriented health and hygiene players. For many portfolio managers, the stock can serve as a stabilizing element with exposure to structural themes such as aging, urbanization, and hygiene awareness.

Future performance will depend on several factors. On the cost side, pulp, energy, and logistics pricing remain key variables that can pressure margins if not offset by productivity gains and pricing measures. On the demand side, competitive dynamics from other global and regional hygiene producers can influence market share and pricing in tissue and personal care categories. Essitys continued focus on branded innovation, efficiency programs, and sustainability could be crucial in maintaining the margin improvements recorded in the 2025 EBITDA and EBIT metrics.

Investors will also monitor Essitys leverage trajectory and capital spending plans. With net debt to EBITDA falling to 2.1 times at the end of 2025 from 2.5 times in 2024, the company has demonstrated progress in deleveraging, supported by higher cash flow. The proposed dividend increase to SEK 8.00 per share, representing a 14.3 percent uplift, signals confidence in cash generation but also requires ongoing discipline to balance shareholder returns with investments in capacity, digital solutions, and new product development.

Ultimately, Essity B stock reflects a company that has navigated inflationary and currency challenges while strengthening its earnings profile and preserving financial flexibility. If the group can sustain organic growth in key product categories such as TENA, maintain or further improve margins, and continue to deleverage at a measured pace, its trading range between the 52-week low of SEK 245.20 and high of SEK 298.60 could shift as investors reassess the long term risk and reward balance. For now, the 2025 figures and mid-2026 price levels provide a concrete snapshot of Essitys position in the global hygiene and health market.

TENA and hygiene portfolio

Essitys TENA products and broader hygiene portfolio, encompassing tissue, personal care, and professional hygiene solutions, remain central to the companys strategy as it seeks durable growth and margin resilience.

Essity B stock price snapshot

As of 30 June 2026, Essity B stock closed at SEK 280.40 on Nasdaq Stockholm, implying a market capitalization around SEK 193 billion and reflecting a position between the 52-week low of SEK 245.20 and high of SEK 298.60.